<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098527</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02637</org_study_id>
    <secondary_id>6075-04-7R0</secondary_id>
    <secondary_id>DUMC-6075-04-7R0</secondary_id>
    <secondary_id>CDR0000398177</secondary_id>
    <secondary_id>NCI-6351</secondary_id>
    <secondary_id>U01CA099118</secondary_id>
    <nct_id>NCT00098527</nct_id>
  </id_info>
  <brief_title>FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well FR901228 works in treating patients with refractory&#xD;
      stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for their growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the radiographic response rate (complete response and partial response) in&#xD;
      patients with refractory adenocarcinoma of the stomach or gastroesophageal junction treated&#xD;
      with FR901228 (depsipeptide).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the median time to progression and progression-free survival of patients treated&#xD;
      with this drug.&#xD;
&#xD;
      II. Determine the grade 3 and 4 toxic effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 13-20 patients will be accrued for this study within 6.5-10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic response rate (complete response &amp; partial response)</measure>
    <time_frame>Not Provided</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) according to RECIST</measure>
    <time_frame>Up to more than 6 months</time_frame>
    <description>The median time to progression and median PFS for all eligible patients, along with their CIs, will be reported. The Kaplan-Meier analysis approach may be used to summarize these time-to-event endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment related grade 1-4 toxicities and cardiac toxicities as assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of changes in gene expression profile in dermal granulation tissue pre- and post-treatment with gene expression profile</measure>
    <time_frame>Not Provided</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of wound vascular scores pre- and post-treatment with gene/protein changes</measure>
    <time_frame>Not Provided</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Not Provided</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression profile</measure>
    <time_frame>At pre- and post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of p21 and thymidine kinase expression, and tubulin acetylation using Western blotting</measure>
    <time_frame>From baseline to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression profile in dermal granulation tissue</measure>
    <time_frame>From baseline to up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma and urine TGFB levels</measure>
    <time_frame>At pre-and post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adenocarcinoma of the Esophagus</condition>
  <condition>Adenocarcinoma of the Stomach</condition>
  <condition>Recurrent Esophageal Cancer</condition>
  <condition>Recurrent Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (romidepsin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the stomach or&#xD;
             gastroesophageal junction&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Refractory* to at least 1, but no more than 3, of the following first-line agents:&#xD;
&#xD;
               -  Fluoropyrimidine (e.g., capecitabine or fluorouracil)&#xD;
&#xD;
               -  Taxane (e.g., paclitaxel or docetaxel)&#xD;
&#xD;
               -  Platinum (e.g., carboplatin, cisplatin, or oxaliplatin)&#xD;
&#xD;
          -  No known active brain metastases&#xD;
&#xD;
               -  Treated brain metastases allowed provided metastases are stable off steroids for&#xD;
                  ≥ 30 days&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No ventricular arrhythmias requiring medication&#xD;
&#xD;
          -  No angioplasty or vascular stenting within the past 3 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No left ventricular hypertrophy by EKG&#xD;
&#xD;
          -  No known history of serious ventricular arrhythmia (e.g., ventricular tachycardia or&#xD;
             ventricular fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA or echocardiogram&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Potassium ≥ 4.0 mmol/L (stable level with no change in supplementation within the past&#xD;
             2 weeks)&#xD;
&#xD;
          -  Magnesium ≥ 2.0 mg/dL (stable level with no change in supplementation within the past&#xD;
             2 weeks)&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to study drug&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  Prior biological agents allowed&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF)&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Prior targeted agents allowed&#xD;
&#xD;
          -  No other prior or concurrent cytotoxic agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent medications causing QTc prolongation&#xD;
&#xD;
          -  No concurrent potassium supplementation &gt; 40 mg/day or magnesium supplementation &gt; 1&#xD;
             g/week&#xD;
&#xD;
          -  No concurrent hydrochlorothiazide&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Hurwitz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

